Name (Synonyms) | Correlation | |
---|---|---|
D018746 | Systemic Inflammatory Response Syndrome NIH | 0.58 |
D009102 | Multiple Organ Failure NIH | 0.58 |
D058186 | Acute Kidney Injury NIH | 0.41 |
D013577 | Syndrome NIH | 0.13 |
D055371 | Acute Lung Injury NIH | 0.13 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.13 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
There is one clinical trial.
To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo
Description: Changes of the level of Tumor Necrosis Factor (TNF), interleukin IL8,IL6,IL10 from the baseline values
Measure: Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks ) Time: 4 weeksDescription: The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo
Measure: Mortality rate Time: from the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to two monthsDescription: Change of viral load from Baseline
Measure: Determine viral load in each patient Time: 4 weeksDescription: Time of discharge from hospital after full recovery
Measure: clinical improvement and hospital discharge Time: from the date of assignment until the date of hospital discharge for the last assigned case, whichever comes first, assessed up to two months